ReviewMolecules (Basel, Switzerland)2018
Use of Cyclodextrins in Anticancer Photodynamic Therapy Treatment.
Review in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 55 citations in OpenAlex.
- Hypoxia-responsive supramolecular systems based on macrocycles and self-assembly structures.Medical gas research · 2027Review
- Water-soluble cationic porphyrins with enhanced phototoxicity to cancer cell lines for G4-targeting photodynamic therapy.RSC medicinal chemistry · 2026Article
- Ce6 derivative photodynamic therapy triggers PANoptosis and enhances antitumor immunity with LAG3 blockade in cutaneous squamous cell carcinoma.Cell reports. Medicine · 2025Article
- Synthetic Receptors for Early Detection and Treatment of Cancer.Biosensors · 2023Review
- A supramolecular nanoplatform for imaging-guided phototherapiesChemical science · 2023Article
- Ιnclusion Complexes of Magnesium Phthalocyanine with Cyclodextrins as Potential Photosensitizing Agents.Bioengineering (Basel, Switzerland) · 2023Article
- Cyclodextrin-Based Nanoplatforms for Tumor Phototherapy: An Update.Pharmaceutics · 2022Review
- Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Some Natural Photosensitizers and Their Medicinal Properties for Use in Photodynamic Therapy.Molecules (Basel, Switzerland) · 2022Review
- Article
- Modulation of Temoporfin Distribution in Blood by β-Cyclodextrin Nanoshuttles.Pharmaceutics · 2021Article
- Probing the Interactions of Porphyrins with Macromolecules Using NMR Spectroscopy Techniques.Molecules (Basel, Switzerland) · 2021Review
- Facile synthesis of per(6-O-tert-butyldimethylsilyl)-α-, β-, and γ-cyclodextrin as protected intermediates for the functionalization of the secondary face of the macrocycles.Nature protocols · 2021Article
- Cyclodextrin-based delivery systems for in vivo-tested anticancer therapies.Drug delivery and translational research · 2021Review
- Ligand-Targeted Delivery of Photosensitizers for Cancer Treatment.Molecules (Basel, Switzerland) · 2020Review
- Natural Ingredient-Based Polymeric Nanoparticles for Cancer Treatment.Molecules (Basel, Switzerland) · 2020Review
- Rational design of block copolymer self-assemblies in photodynamic therapy.Beilstein journal of nanotechnology · 2020Review
- New Targeted Gold Nanorods for the Treatment of Glioblastoma by Photodynamic Therapy.Journal of clinical medicine · 2019Article
- A Molecular Dynamics Study of a Photodynamic Sensitizer for Cancer Cells: Inclusion Complexes of γ-Cyclodextrins with CInternational journal of molecular sciences · 2019Article
- Introduction to "Advances in Photodynamic Therapy 2018".Molecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy (PDT) is mainly used to destroy cancerous cells; it combines the action of three components: a photoactivatable molecule or photosensitizer (PS), the light of an appropriate wavelength, and naturally occurring molecular oxygen. After light excitation of the PS, the excited PS then reacts with molecular oxygen to produce reactive oxygen species (ROS), leading to cellular damage. One of the drawbacks of PSs is their lack of solubility in water and body tissue fluids, thereby causing low bioavailability, drug-delivery efficiency, therapeutic efficacy, and ROS production. To improve the water-solubility and/or drug delivery of PSs, using cyclodextrins (CDs) is an interesting strategy. This review describes the in vitro or/and in vivo use of natural and derived CDs to improve antitumoral PDT efficiency in aqueous media. To achieve these goals, three types of binding modes of PSs with CDs are developed: non-covalent CD⁻PS inclusion complexes, covalent CD⁻PS conjugates, and CD⁻PS nanoassemblies. This review is divided into three parts: (1) non-covalent CD-PS inclusion complexes, covalent CD⁻PS conjugates, and CD⁻PS nanoassemblies, (2) incorporating CD⁻PS systems into hybrid nanoparticles (NPs) using up-converting or other types of NPs, and (3) CDs with fullerenes as PSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.